Multi-Organ Failure in Cirrhosis: When Standard Support Stops Being Enough
A cirrhotic patient's acute-on-chronic liver failure is progressing fast enough that standard vasopressor and renal support may not be the whole plan much longer. The disagreement is about timing, and about whether the transplant conversation is keeping pace with everything else happening in the room.
Bernard K., a 59-year-old man, ran a small print shop until decompensated alcohol-associated cirrhosis forced him to sell it two years ago; his daughter, a nurse in another state, has been on the phone with the ICU team daily since he was admitted four days ago for a variceal bleed that has since been controlled endoscopically. Over the past 48 hours, he has developed rapidly progressing acute-on-chronic liver failure: worsening encephalopathy now requiring intubation for airway protection, rising creatinine despite volume resuscitation, and blood pressure requiring escalating vasopressor support, with his organ-failure count climbing across three systems within a single day.
Standard critical care support — vasopressor titration, renal replacement therapy initiated on usual thresholds — remains the backbone of ACLF management, and extracorporeal liver support modalities remain genuinely contested: RELIEF and HELIOS, the two large randomized trials of albumin dialysis in ACLF, both missed their primary survival endpoints, and the plasma-exchange evidence rests on a smaller trial in acute rather than acute-on-chronic failure. None of it supplies the consistent survival benefit that would make escalation an obvious next step. What makes his case harder than a stable multi-organ-failure picture is the speed: three organ systems failing within roughly a day is a trajectory, not a stable state, and how much time standard support should be given to work before considering something more aggressive is exactly what the team is weighing in real time.
A trajectory, not a stable multi-organ picture
I'd continue escalating norepinephrine and start renal replacement therapy on our usual thresholds, without reaching for albumin dialysis or plasma exchange yet. Those extracorporeal modalities remain genuinely contested — the trial evidence doesn't show a consistent survival benefit across the board — and they carry real added bleeding risk and logistical burden. I want standard support fully optimized before we add that complexity on top of it.
I don't disagree with optimizing standard support first in general, but I'd flag that his specific trajectory — three organ systems in roughly a day — is close to the subpopulation where the trial data on extracorporeal support shows its clearest signal, modest as that signal is. If we wait until standard support has obviously failed before considering it, we may be waiting past the window where it could still help. I'm not arguing to start it today, but I don't want 'not yet' to quietly become 'too late.'
'Fully optimized before adding complexity' is the right instinct for a stable patient, but he isn't stable — he's moving, and I think the pace of his deterioration changes how much runway 'fully optimized' can reasonably mean before it becomes its own kind of delay.
Whatever you two land on for support escalation, I want to name something that hasn't happened yet: transplant candidacy has not been formally assessed, and given how fast he's deteriorating, that assessment needs to run in parallel with this conversation, starting today, not after. A patient moving this quickly may be approaching the point where the most honest next step is a listing decision, and I don't want the vasopressor and renal-support conversation, as important as it is, to be the only thing happening in this room while that window narrows too.
Standard vasopressor escalation and renal replacement therapy initiated. Extracorporeal liver support was not started today but was explicitly documented as under active reconsideration, not closed off, pending his response over the next 24-48 hours.
Transplant evaluation formally opened the same day, run in parallel with ongoing critical care management rather than deferred until his trajectory either stabilizes or clearly forecloses candidacy. Where his course goes from here was left genuinely unresolved, and documented that way rather than implying more certainty than the team actually had.